A World Without Infectious Disease
A new era
We are developing a broad portfolio of product candidates that are designed to combat infectious diseases and other serious conditions, creating medicines that will have a meaningful impact on people around the world.
Hepatitis B
VIR-2218 + PEG-IFN-α
- Collaborator:
- Alnylam
- Treatment Type:
- Treatment
- Phase:
- Phase 2,100%
VIR-3434 ± VIR-2218 ± PEG-IFN-α1
- Collaborator:
- Alnylam
- Treatment Type:
- Treatment
- Phase:
- Phase 2,100%
VIR-2218 + BRII-179
- Collaborator:
- Alnylam / Brii Biosciences
- Treatment Type:
- Treatment
- Phase:
- Phase 2,100%
VIR-2218 + TLR82 + PD-13
- Collaborator:
- Alnylam / Gilead
- Treatment Type:
- Treatment
- Phase:
- Phase 2,100%
Hepatitis Delta
VIR-2218 + VIR-3434
- Collaborator:
- Alnylam
- Treatment Type:
- Treatment
- Phase:
- Phase 2,100%
Influenza A
VIR-2482 (Influenza A)
- Treatment Type:
- Prophylaxis
- Phase:
- Phase 2,100%
VIR-2981 (Influenza A+B)*
- Collaborator:
- GSK
- Treatment Type:
- Prophylaxis
- Phase:
- Pre-clinical,100%
HIV
VIR-1388
- Collaborator:
- BMGF, NIAID and HVTN**
- Treatment Type:
- Treatment
- Phase:
- Phase 1,100%
COVID-19
Sotrovimab***
- Collaborator:
- GSK
- Treatment Type:
- Treatment Early
- Phase:
- Authorized,100%
VIR-7229
- Treatment Type:
- Prophylaxis
- Phase:
- Pre-clinical,100%
RSV/MPV
VIR-8190*
- Collaborator:
- GSK
- Treatment Type:
- Prophylaxis
- Phase:
- Pre-clinical,100%
Pre-cancerous HPV lesions
VIR-1949
- Treatment Type:
- Treatment
- Phase:
- Pre-clinical,100%
1: MARCH trial (Part B), PREVAIL platform trial (THRIVE/STRIVE sub-protocols)
2: GS-9688
3: nivolumab
* Per the collaboration agreement announced in February 2021, Vir and GSK are continuing to advance new monoclonal antibody therapeutics for influenza and other respiratory viruses, including RSV
** Bill and Melinda Gates Foundation, National Institute of Allergy and Infectious Diseases, and HIV Vaccine Trials Network
*** Sotrovimab for early treatment by IV currently has marketing approval, temporary authorization or emergency use authorization in >40 countries. In April 2022, the FDA deauthorized sotrovimab‘s use in all US regions.
